Dr Skoulidis obtained a Medical Degree from the Aristotle University of Thessaloniki, Greece in 2000 and a PhD from the University of Cambridge, UK in 2011. He completed general medicine residency and medical oncology fellowship training in Cambridge and London, UK before moving to the University of Texas MD Anderson Cancer Center, where he is currently a Tenured Associate Professor (Physician Scientist) in the Department of Thoracic/Head and Neck Medical Oncology. Dr Skoulidis’ laboratory is focused on (a) elucidating mechanisms and biomarkers of response and tolerance to direct RAS inhibitors; (b) unraveling the molecular and clinical heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) and (c) dissecting the impact of individual somatic genomic alterations – with a focus on STK11 and KEAP1 - on the NSCLC immune contexture and immunotherapy response. His early work delineated the role of co-mutations on the molecular diversity of KRAS -mutant NSCLC and identified somatic mutations in STK11 as the most prevalent genomic driver of primary resistance to PD-1/PD-L1 blockade in non-squamous NSCLC. Recent work from the Skoulidis laboratory identified a novel gastric/mucinous transcriptional program that supports RAS inhibitor tolerance (Araujo HA et al., Cancer Discovery, 2024)  and established dual ICB with anti-PD-(L)1/anti-CTLA-4 as a strategy to mitigate primary PD-(L)1 inhibitor resistance in patients with STK11 and/or KEAP1-mutated tumors (Skoulidis F et al., Nature, 2024). Dr Skoulidis played a leading role in the clinical development of sotorasib that resulted in the first FDA approval of a direct RAS inhibitor in May 2021 (Skoulidis F et al., New Engl. J. Med, 2021) and is currently involved in several registrational clinical trials of novel RAS inhibitors. Dr Skoulidis has received several awards including a 2019 AACR NextGen Star award and his research has attracted funding from the NIH/NCI, CPRIT and the US Department of Defense.